JP2016518351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518351A5 JP2016518351A5 JP2016506352A JP2016506352A JP2016518351A5 JP 2016518351 A5 JP2016518351 A5 JP 2016518351A5 JP 2016506352 A JP2016506352 A JP 2016506352A JP 2016506352 A JP2016506352 A JP 2016506352A JP 2016518351 A5 JP2016518351 A5 JP 2016518351A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- acid
- group
- lys
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000539 dimer Substances 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 39
- 150000008574 D-amino acids Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- -1 heteroaromatic amino acid Chemical class 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims description 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 6
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 claims description 3
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 claims description 3
- IEXKUCOGQITOPO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEXKUCOGQITOPO-UHFFFAOYSA-N 0.000 claims description 3
- GDYYIJNDPMFMTB-UHFFFAOYSA-N 2-[3-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(CC(O)=O)=C1 GDYYIJNDPMFMTB-UHFFFAOYSA-N 0.000 claims description 3
- SLWIPPZWFZGHEU-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CC(O)=O)C=C1 SLWIPPZWFZGHEU-UHFFFAOYSA-N 0.000 claims description 3
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 3
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 claims description 3
- NCFSMLBHQUAMHH-UHFFFAOYSA-N C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O Chemical compound C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O NCFSMLBHQUAMHH-UHFFFAOYSA-N 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 150000007824 aliphatic compounds Chemical class 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001491 aromatic compounds Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 150000002390 heteroarenes Chemical class 0.000 claims description 3
- 230000011987 methylation Effects 0.000 claims description 3
- 238000007069 methylation reaction Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000023819 chronic asthma Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 208000008275 microscopic colitis Diseases 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical group OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical group 0.000 claims 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940122065 Alpha4beta7 integrin antagonist Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 description 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 1
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005516 glycogen storage disease Ib Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807714P | 2013-04-02 | 2013-04-02 | |
| US61/807,714 | 2013-04-02 | ||
| US14/229,784 | 2014-03-28 | ||
| US14/229,784 US20140294901A1 (en) | 2013-04-02 | 2014-03-28 | Novel a4b7 peptide dimer antagonists |
| PCT/US2014/032391 WO2014165448A1 (en) | 2013-04-02 | 2014-03-31 | NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518351A JP2016518351A (ja) | 2016-06-23 |
| JP2016518351A5 true JP2016518351A5 (enExample) | 2017-04-27 |
| JP6499157B2 JP6499157B2 (ja) | 2019-04-10 |
Family
ID=51621089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506352A Active JP6499157B2 (ja) | 2013-04-02 | 2014-03-31 | 新規のα４β７ペプチド二量体アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20140294901A1 (enExample) |
| EP (1) | EP2981544B1 (enExample) |
| JP (1) | JP6499157B2 (enExample) |
| KR (1) | KR20160011625A (enExample) |
| CN (1) | CN105339383A (enExample) |
| AU (2) | AU2014248321A1 (enExample) |
| CA (1) | CA2908593A1 (enExample) |
| HK (1) | HK1221233A1 (enExample) |
| SG (2) | SG10201708103RA (enExample) |
| WO (1) | WO2014165448A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| RS62633B1 (sr) | 2013-03-15 | 2021-12-31 | Protagonist Therapeutics Inc | Analozi hepcidina i njihove primene |
| SI3143037T1 (sl) | 2014-05-16 | 2021-11-30 | Protagonist Therapeutics, Inc. | Antagonisti integrin alpha4beta7 tioeterskih peptidov |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CN108699110B (zh) * | 2015-10-23 | 2023-04-28 | 特温特大学 | 整合素结合肽及其用途 |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2017165676A1 (en) * | 2016-03-23 | 2017-09-28 | Protagonist Therapeutics, Inc. | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS |
| EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3820883A4 (en) | 2018-07-12 | 2022-04-20 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CN116082455A (zh) | 2019-07-10 | 2023-05-09 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| EP4090669A4 (en) | 2020-01-15 | 2024-11-20 | Janssen Biotech, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
| SI4090670T1 (sl) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni |
| IL316550A (en) | 2020-11-20 | 2024-12-01 | Janssen Pharmaceutica Nv | Compositions of interleukin-23 receptor peptide inhibitors |
| IL310061A (en) | 2021-07-14 | 2024-03-01 | Janssen Biotech Inc | Peptide inhibitors linked to fatty residues of the interleukin-23 receptor |
| CN114874107B (zh) * | 2022-07-12 | 2022-11-29 | 中山大学附属第七医院(深圳) | 一种氨基脂质及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| GB9613112D0 (en) * | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| US6818617B1 (en) * | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| EP1033983A1 (en) * | 1997-11-24 | 2000-09-13 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| CA2436326C (en) * | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| GB0610395D0 (en) * | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| EP2109480B1 (en) * | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
| WO2009039185A1 (en) * | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| JP2011231085A (ja) * | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| EP2444101A1 (en) * | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
-
2014
- 2014-03-28 US US14/229,784 patent/US20140294901A1/en not_active Abandoned
- 2014-03-31 SG SG10201708103RA patent/SG10201708103RA/en unknown
- 2014-03-31 WO PCT/US2014/032391 patent/WO2014165448A1/en not_active Ceased
- 2014-03-31 CA CA2908593A patent/CA2908593A1/en not_active Abandoned
- 2014-03-31 SG SG11201508178UA patent/SG11201508178UA/en unknown
- 2014-03-31 HK HK16109329.5A patent/HK1221233A1/zh unknown
- 2014-03-31 EP EP14779463.0A patent/EP2981544B1/en active Active
- 2014-03-31 AU AU2014248321A patent/AU2014248321A1/en not_active Abandoned
- 2014-03-31 JP JP2016506352A patent/JP6499157B2/ja active Active
- 2014-03-31 KR KR1020157031177A patent/KR20160011625A/ko not_active Withdrawn
- 2014-03-31 CN CN201480028920.2A patent/CN105339383A/zh active Pending
-
2017
- 2017-12-08 US US15/836,648 patent/US20190002500A1/en not_active Abandoned
-
2018
- 2018-08-27 AU AU2018220168A patent/AU2018220168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518351A5 (enExample) | ||
| JP2016515620A5 (enExample) | ||
| JP2017522362A5 (enExample) | ||
| RU2017114414A (ru) | НОВЫЕ АНТАГОНИСТЫ α4β7 НА ОСНОВЕ МОНОМЕРНЫХ И ДИМЕРНЫХ ПЕПТИДОВ | |
| JP2015533833A5 (enExample) | ||
| JP2017535527A5 (enExample) | ||
| JP6849720B2 (ja) | グルカゴン類似体 | |
| TWI674271B (zh) | 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物 | |
| US12077612B2 (en) | Peptide compositions | |
| TWI608013B (zh) | 升糖素類似物 | |
| JP2025163134A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| AU2014228460B2 (en) | Pharmaceutical compositions | |
| JP6499157B2 (ja) | 新規のα４β７ペプチド二量体アンタゴニスト | |
| JP2012067099A5 (enExample) | ||
| AU2015258863B2 (en) | Alpha4beta7 integrin thioether peptide antagonists | |
| CA2955460A1 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| JP2017530090A5 (enExample) | ||
| JP2016515620A (ja) | 新規のα４β７ペプチド拮抗薬 | |
| JP2012529296A5 (enExample) | ||
| WO2022188628A1 (zh) | 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用 | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| WO2025137159A1 (en) | Human interleukin (il)-17 cytokine binding peptides | |
| WO2026060110A1 (en) | Dual- and tri-agonist compounds for obesity & t2dm | |
| HK40046859A (en) | Pharmaceutical compositions | |
| HK40006194A (en) | Peptide compositions |